Size | Price | Stock | Qty |
---|---|---|---|
250mg |
|
||
500mg |
|
||
1g |
|
||
2g |
|
||
5g |
|
||
Other Sizes |
|
Purity: ≥98%
Fluocinolone Acetonide (Flucort-N; Flucinar, Fluonid, Synandone, Jellin, Sinalar) is a topical and synthetic glucocorticoid with with anti-inflammatory and immunomodulating properties. It is used topically in the treatment of various skin disorders. Studies indicate that Fluocinolone Acetonide can inhibit promotion of tumor cells at an early stage of promotion if combined with a promoting agent. In addition, studies suggest that Fluocinolone Acetonide can regulate lipid metabolism by modulating gene expression. Alternate studies show that Fluocinolone Acetonide can inhibit the expression of VEGF (vascular endothelial growth factor) in the retinal pigment epithelial cell line due to its high glucocorticoid receptor affinity.
ln Vitro |
The survival rate of foam cells can be increased with fluocinolone (0.1–50 μg/mL, for two days)[1]. Fluocinolone (0.1–50 μg/mL, 2 days) lowers the build-up of cholesterol ester and suppresses the release of inflammatory cytokines [1]. Fluocinolone (0.1-100 μmol/L, 24 h) stimulates DPC growth [2]. Fluocinolone (1–10 μmol/L, 7 days) upregulates the expression of dentin-specific marker dentin sialophosphoprotein and upregulates BSP, OCN, DSPP, and Wnt4 [2].
|
---|---|
ln Vivo |
In a mouse model produced by PTX, fluocinolone (500 μg/kg, intraperitoneal injection, once daily for two weeks) inhibited the development of severe peripheral neuropathy [3].
|
Cell Assay |
Cell Proliferation Assay[2]
Cell Types: DCPs Tested Concentrations: 0.1 μmol/L, 1 μmol/L, 10 μmol/L, 20 μmol/L, 40 μmol/L, 60 μmol/L, 100 μmol/L Incubation Duration: 24 h Experimental Results: Dramatically promoted the growth rate of DPCs of a low concentration. Western Blot Analysis[2] Cell Types: DCPs Tested Concentrations: 1 μmol/L, 10 μmol/L Incubation Duration: 7 days Experimental Results: demonstrated higher expressions of DSPP and Wnt4 protein than negative control. |
Animal Protocol |
Animal/Disease Models: PTX-induced peripheral neuropathy model [3]
Doses: 500 μg/kg Route of Administration: intraperitoneal (ip)injection Experimental Results: Prevented a marked reduction in intraepidermal nerve fibers density in the plantar surface of the hind paws. |
References |
[1]. Nguyen L T H, et al. The potential of fluocinolone acetonide to mitigate inflammation and lipid accumulation in 2D and 3D foam cell cultures [J]. BioMed Research International, 2018, 2018.
[2]. Liu Z, et al. Fluocinolone acetonide promotes the proliferation and mineralization of dental pulp cells [J]. Journal of endodontics, 2013, 39(2): 217-222. [3]. Cetinkaya-Fisgin A, et al. Identification of fluocinolone acetonide to prevent paclitaxel‐induced peripheral neuropathy [J]. Journal of the Peripheral Nervous System, 2016, 21(3): 128-133. [4]. Nehmé A, et al. Glucocorticoids with different chemical structures but similar glucocorticoid receptor potency regulate subsets of common and unique genes in human trabecular meshwork cells [J]. BMC medical genomics, 2009, 2(1): 1-14. [5]. http://en.wikipedia.org/wiki/Fluocinolone_acetonide [6]. Nehme, A., et al., Glucocorticoids with different chemical structures but similar glucocorticoid receptor potency regulate subsets of common and unique genes in human trabecular meshwork cells. BMC Med Genomics, 2009. 2: p. 58. |
Molecular Formula |
C24H30F2O6
|
|
---|---|---|
Molecular Weight |
452.49
|
|
CAS # |
67-73-2
|
|
Related CAS # |
|
|
SMILES |
F[C@@]12[C@]3(C([H])=C([H])C(C([H])=C3[C@]([H])(C([H])([H])[C@@]1([H])[C@]1([H])C([H])([H])[C@]3([H])[C@](C(C([H])([H])O[H])=O)([C@@]1(C([H])([H])[H])C([H])([H])[C@]2([H])O[H])OC(C([H])([H])[H])(C([H])([H])[H])O3)F)=O)C([H])([H])[H]
|
|
InChi Key |
FEBLZLNTKCEFIT-VSXGLTOVSA-N
|
|
InChi Code |
InChI=1S/C24H30F2O6/c1-20(2)31-19-9-13-14-8-16(25)15-7-12(28)5-6-21(15,3)23(14,26)17(29)10-22(13,4)24(19,32-20)18(30)11-27/h5-7,13-14,16-17,19,27,29H,8-11H2,1-4H3/t13-,14-,16-,17-,19+,21-,22-,23-,24+/m0/s1
|
|
Chemical Name |
(1S,2S,4R,8S,9S,11S,12R,13S,19S)-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-6,6,9,13-tetramethyl-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one
|
|
Synonyms |
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
|||
---|---|---|---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (4.60 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (4.60 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (4.60 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.2100 mL | 11.0500 mL | 22.0999 mL | |
5 mM | 0.4420 mL | 2.2100 mL | 4.4200 mL | |
10 mM | 0.2210 mL | 1.1050 mL | 2.2100 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.